Market Cap 144.11M
Revenue (ttm) 118.71M
Net Income (ttm) -30.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 750.00
Profit Margin -25.59%
Debt to Equity Ratio 0.52
Volume 110,900
Avg Vol 267,030
Day's Range N/A - N/A
Shares Out 6.45M
Stochastic %K 99%
Beta 0.44
Analysts Hold
Price Target $22.60

Company Profile

Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut sy...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 224 419 7106
Fax: 510 744 8001
Address:
100 South Saunders Road, Suite 300, Lake Forest, United States
DARKP00L
DARKP00L May. 13 at 12:03 PM
$ASRT 08:01 on May. 13 2026 Assertio Agrees To Be Acquired By Zydus Worldwide For $23.50 Per Share In Cash #tradeideas
0 · Reply
DARKP00L
DARKP00L May. 13 at 12:03 PM
$ASRT 07:55 on May. 13 2026 Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending #tradeideas
0 · Reply
TwongStocks
TwongStocks May. 13 at 12:01 PM
$ASRT Assertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash https://www.businesswire.com/news/home/20260513899186/en/Assertio-to-Be-Acquired-by-Zydus-Worldwide-DMCC-for-%2423.50-Per-Share-in-Cash • All-Cash Tender Offer of $23.50 per share or $166.4 Million • Offer Represents 30.6% Premium to Original Agreement with Garda Therapeutics AND 75.8% Premium to Unaffected Price
0 · Reply
Chuckuk
Chuckuk May. 13 at 11:30 AM
$ASRT I know this is tiresome but some, like me, have a huge amount in this stock bought and held, because of the positive conference call comments. They then suddenly find the Board backs a deal, which has already been discredited once and raised, well below any implied value from the opinions offered by those calls. Plus the very fact that the last drug standing was bought by the Board for say $250M to be then sold for much less by that very same Board's recommendation. It is very troubling so sorry I keep banging on but "if it smells like fish" as they say! Sadly for them I am not a penguin and neither are most of you!
0 · Reply
Chuckuk
Chuckuk May. 13 at 11:13 AM
$ASRT So the intial Tender Offer, then Market test, then the next offer and ditto all the time the share register will show who has bought/sold and what the split is verus held and traded. So they know (ish) the numbers if not enough holders have been teased out another offer will come without the actual Tender to get more out. Once the market price and the identified holders have been determined the point at which 50% is reached will crystalize the Tender issue and follow through. The 14d-9 will say some stuff around justifying this and a view as to value and issues, it needs to be 'right' but can be pessimistic, that will again colour the detail. There is more here yet I think and the previous analysts' estimates up to the $40 mark might help. Moelis will have to show balance and that is what might show where the true answer lies. The well built lady will sing some will cry and some will be happy but maybe part of this is to avoid legal challenge. Sold shares lose the legal lever.
0 · Reply
Chuckuk
Chuckuk May. 13 at 10:49 AM
$ASRT Next post Then Garda removed the CVR in the amended $21.80 offer, so the public shareholders lost that direct Sprix-linked upside. So I would revise the earlier view slightly: $28 looks more plausible than it first appears, because on a net-cash basis it may still only value the operating/residual business around the low-$100M area. $35 is still a stretch, but not absurd if you believe Rolvedon plus retained Cosette economics and cash should command more than $150M net. The sharp shareholder question is: Why is $21.80 fair when Garda is acquiring a company required to deliver at least $95M of Closing Net Cash, after a $35M Cosette asset sale, and with any non-shareholder Cosette economics potentially benefiting the surviving company rather than current public holders?
0 · Reply
Chuckuk
Chuckuk May. 13 at 10:48 AM
$ASRT Using the stated $153.2M total cash consideration at $21.80: Offer price Implied equity cheque Less $95M Closing Net Cash Rough net cost before debt/other adjustments $21.80 $153.2M -$95M c. $58.2M $28.00 c. $196.8M -$95M c. $101.8M $35.00 c. $246.0M -$95M c. $151.0M So, seen properly, a move from $21.80 to $28 is not Garda paying $196.8M for Rolvedon. It is more like paying about $102M net of the required closing cash, before allowing for notes, transaction costs and future receipts. A move to $35 would be nearer $151M net of closing cash. That is why your argument has more force than the headline price suggests. Assertio sold the non-Rolvedon assets to Cosette for $35M upfront plus earnouts, including Indocin, Sympazan, Sprix, Cambia, Zipsor and Otrexup. The original structure said Sprix-related milestones would pass to shareholders via the CVR, while other Cosette economics would not further change the purchase price. see next
0 · Reply
Chuckuk
Chuckuk May. 13 at 10:07 AM
$ASRT So your thesis is plausible in market-structure terms: $18 “teaser” → weak holders sell → $21.80 revised offer → more holders sell above offer → possible final bump if tender resistance or rival pressure remains. However, I would not assume $30 is the planned number. A move to $30 would be a very large jump from $21.80 — about 37.6% higher — and would likely require either a real competing bidder, a failed/weak tender response, or the 14D-9 showing valuation/process facts that make $21.80 indefensible. The current agreement still says $21.80 and remains subject to a majority of outstanding shares being tendered. My best read: yes, the shareholder base may have been deliberately or naturally reshaped by the low offer and then the bump. But if ASRT is still holding around $22.50 before the 14D-9, that suggests the reshaping has not fully solved Garda’s problem. Buyers at $22-plus are not buying to accept $21.80; they are buying because they think there is still optionality.
0 · Reply
Chuckuk
Chuckuk May. 13 at 9:57 AM
$ASRT Might be hard to get the 51% at this level, not enough institutions to get it there it may need to be double the Tender offer that could just yield enough to meet the 51% but in cash terms that is still half price as the cash and benefit in the business halves the price. Of course this is the key the Tender is the problem as all tenderers will get the final price whereas you could buy up on the open market but as is the case now the price will climb as resistance increases and volume declines. The high value holders will be the ones left with the Tender seeking to squeeze them out so I see now why the market is buying in the expectation the tender will need to increase. Those inclined to accept will have sold on the market. So buy at $22 sell at $30 or more.
0 · Reply
Chuckuk
Chuckuk May. 13 at 9:44 AM
$ASRT So that was 35% of shares issued back when the deal happened diluted a bit now and maybe some got out in June 2023 when we were at $105 ie $7
0 · Reply
Latest News on ASRT
Assertio, Garda agree to delay launch of tender offer

2026-05-08T17:52:08.000Z - 4 days ago

Assertio, Garda agree to delay launch of tender offer


Assertio Provides Update on Garda Therapeutics Tender Process

Apr 21, 2026, 5:00 PM EDT - 21 days ago

Assertio Provides Update on Garda Therapeutics Tender Process


Assertio downgraded to Hold from Buy at Maxim

2026-04-09T17:35:14.000Z - 4 weeks ago

Assertio downgraded to Hold from Buy at Maxim


Assertio downgraded to Hold from Buy at Lake Street

2026-04-09T13:04:39.000Z - 4 weeks ago

Assertio downgraded to Hold from Buy at Lake Street


Assertio downgraded to Neutral from Buy at H.C. Wainwright

2026-04-09T10:12:06.000Z - 4 weeks ago

Assertio downgraded to Neutral from Buy at H.C. Wainwright


Assertio Holdings Earnings Call Transcript: Q4 2025

Mar 16, 2026, 4:30 PM EDT - 2 months ago

Assertio Holdings Earnings Call Transcript: Q4 2025


Assertio regains compliance with Nasdaq listing requirements

2026-01-12T21:21:26.000Z - 4 months ago

Assertio regains compliance with Nasdaq listing requirements


Assertio Therapeutics trading halted, news pending

2025-12-24T21:50:25.000Z - 4 months ago

Assertio Therapeutics trading halted, news pending


Assertio announces one-for-fifteen reverse stock split

2025-12-22T21:36:17.000Z - 5 months ago

Assertio announces one-for-fifteen reverse stock split


Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split

Dec 22, 2025, 4:30 PM EST - 5 months ago

Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split


Assertio Holdings Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:30 PM EST - 6 months ago

Assertio Holdings Earnings Call Transcript: Q3 2025


Assertio Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 4:13 PM EST - 6 months ago

Assertio Reports Third Quarter 2025 Financial Results


Assertio Announces Leadership Transition

Oct 28, 2025, 9:15 AM EDT - 7 months ago

Assertio Announces Leadership Transition


Assertio Holdings Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 9 months ago

Assertio Holdings Earnings Call Transcript: Q2 2025


Assertio Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:05 PM EDT - 9 months ago

Assertio Reports Second Quarter 2025 Financial Results


Assertio Holdings Earnings Call Transcript: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Assertio Holdings Earnings Call Transcript: Q1 2025


Assertio Reports First Quarter 2025 Financial Results

May 12, 2025, 4:01 PM EDT - 1 year ago

Assertio Reports First Quarter 2025 Financial Results


Assertio Holdings Earnings Call Transcript: Q4 2024

Mar 12, 2025, 4:30 PM EDT - 1 year ago

Assertio Holdings Earnings Call Transcript: Q4 2024


Assertio Holdings Earnings Call Transcript: Q3 2024

Nov 11, 2024, 4:30 PM EST - 1 year ago

Assertio Holdings Earnings Call Transcript: Q3 2024


Assertio Reports Third Quarter 2024 Financial Results

Nov 11, 2024, 4:02 PM EST - 1 year ago

Assertio Reports Third Quarter 2024 Financial Results


Assertio Provides Response to Letter from Short-seller

Nov 11, 2024, 7:30 AM EST - 1 year ago

Assertio Provides Response to Letter from Short-seller


Assertio Holdings Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Assertio Holdings Earnings Call Transcript: Q2 2024


Assertio Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Assertio Reports Second Quarter 2024 Financial Results


DARKP00L
DARKP00L May. 13 at 12:03 PM
$ASRT 08:01 on May. 13 2026 Assertio Agrees To Be Acquired By Zydus Worldwide For $23.50 Per Share In Cash #tradeideas
0 · Reply
DARKP00L
DARKP00L May. 13 at 12:03 PM
$ASRT 07:55 on May. 13 2026 Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending #tradeideas
0 · Reply
TwongStocks
TwongStocks May. 13 at 12:01 PM
$ASRT Assertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash https://www.businesswire.com/news/home/20260513899186/en/Assertio-to-Be-Acquired-by-Zydus-Worldwide-DMCC-for-%2423.50-Per-Share-in-Cash • All-Cash Tender Offer of $23.50 per share or $166.4 Million • Offer Represents 30.6% Premium to Original Agreement with Garda Therapeutics AND 75.8% Premium to Unaffected Price
0 · Reply
Chuckuk
Chuckuk May. 13 at 11:30 AM
$ASRT I know this is tiresome but some, like me, have a huge amount in this stock bought and held, because of the positive conference call comments. They then suddenly find the Board backs a deal, which has already been discredited once and raised, well below any implied value from the opinions offered by those calls. Plus the very fact that the last drug standing was bought by the Board for say $250M to be then sold for much less by that very same Board's recommendation. It is very troubling so sorry I keep banging on but "if it smells like fish" as they say! Sadly for them I am not a penguin and neither are most of you!
0 · Reply
Chuckuk
Chuckuk May. 13 at 11:13 AM
$ASRT So the intial Tender Offer, then Market test, then the next offer and ditto all the time the share register will show who has bought/sold and what the split is verus held and traded. So they know (ish) the numbers if not enough holders have been teased out another offer will come without the actual Tender to get more out. Once the market price and the identified holders have been determined the point at which 50% is reached will crystalize the Tender issue and follow through. The 14d-9 will say some stuff around justifying this and a view as to value and issues, it needs to be 'right' but can be pessimistic, that will again colour the detail. There is more here yet I think and the previous analysts' estimates up to the $40 mark might help. Moelis will have to show balance and that is what might show where the true answer lies. The well built lady will sing some will cry and some will be happy but maybe part of this is to avoid legal challenge. Sold shares lose the legal lever.
0 · Reply
Chuckuk
Chuckuk May. 13 at 10:49 AM
$ASRT Next post Then Garda removed the CVR in the amended $21.80 offer, so the public shareholders lost that direct Sprix-linked upside. So I would revise the earlier view slightly: $28 looks more plausible than it first appears, because on a net-cash basis it may still only value the operating/residual business around the low-$100M area. $35 is still a stretch, but not absurd if you believe Rolvedon plus retained Cosette economics and cash should command more than $150M net. The sharp shareholder question is: Why is $21.80 fair when Garda is acquiring a company required to deliver at least $95M of Closing Net Cash, after a $35M Cosette asset sale, and with any non-shareholder Cosette economics potentially benefiting the surviving company rather than current public holders?
0 · Reply
Chuckuk
Chuckuk May. 13 at 10:48 AM
$ASRT Using the stated $153.2M total cash consideration at $21.80: Offer price Implied equity cheque Less $95M Closing Net Cash Rough net cost before debt/other adjustments $21.80 $153.2M -$95M c. $58.2M $28.00 c. $196.8M -$95M c. $101.8M $35.00 c. $246.0M -$95M c. $151.0M So, seen properly, a move from $21.80 to $28 is not Garda paying $196.8M for Rolvedon. It is more like paying about $102M net of the required closing cash, before allowing for notes, transaction costs and future receipts. A move to $35 would be nearer $151M net of closing cash. That is why your argument has more force than the headline price suggests. Assertio sold the non-Rolvedon assets to Cosette for $35M upfront plus earnouts, including Indocin, Sympazan, Sprix, Cambia, Zipsor and Otrexup. The original structure said Sprix-related milestones would pass to shareholders via the CVR, while other Cosette economics would not further change the purchase price. see next
0 · Reply
Chuckuk
Chuckuk May. 13 at 10:07 AM
$ASRT So your thesis is plausible in market-structure terms: $18 “teaser” → weak holders sell → $21.80 revised offer → more holders sell above offer → possible final bump if tender resistance or rival pressure remains. However, I would not assume $30 is the planned number. A move to $30 would be a very large jump from $21.80 — about 37.6% higher — and would likely require either a real competing bidder, a failed/weak tender response, or the 14D-9 showing valuation/process facts that make $21.80 indefensible. The current agreement still says $21.80 and remains subject to a majority of outstanding shares being tendered. My best read: yes, the shareholder base may have been deliberately or naturally reshaped by the low offer and then the bump. But if ASRT is still holding around $22.50 before the 14D-9, that suggests the reshaping has not fully solved Garda’s problem. Buyers at $22-plus are not buying to accept $21.80; they are buying because they think there is still optionality.
0 · Reply
Chuckuk
Chuckuk May. 13 at 9:57 AM
$ASRT Might be hard to get the 51% at this level, not enough institutions to get it there it may need to be double the Tender offer that could just yield enough to meet the 51% but in cash terms that is still half price as the cash and benefit in the business halves the price. Of course this is the key the Tender is the problem as all tenderers will get the final price whereas you could buy up on the open market but as is the case now the price will climb as resistance increases and volume declines. The high value holders will be the ones left with the Tender seeking to squeeze them out so I see now why the market is buying in the expectation the tender will need to increase. Those inclined to accept will have sold on the market. So buy at $22 sell at $30 or more.
0 · Reply
Chuckuk
Chuckuk May. 13 at 9:44 AM
$ASRT So that was 35% of shares issued back when the deal happened diluted a bit now and maybe some got out in June 2023 when we were at $105 ie $7
0 · Reply
Chuckuk
Chuckuk May. 13 at 9:38 AM
$ASRT Former Spectrum shareholders have a very strong economic grievance if they held through. They effectively accepted Assertio paper at something like $96 per current ASRT share, and Garda is now offering $21.80 for the same share class, after Rolvedon became the main remaining asset.
0 · Reply
cjallmountain
cjallmountain May. 12 at 10:38 PM
$ASRT Are we likely to see a news wire announcing further delay to the Tender Offer launch tomorrow I wonder..?
3 · Reply
gain100percent
gain100percent May. 12 at 2:34 PM
$ASRT I set a sell price of $65. They can tender my sell offer
0 · Reply
Chuckuk
Chuckuk May. 12 at 8:13 AM
$ASRT dropped in premarket or after hours on no real volume
0 · Reply
Chuckuk
Chuckuk May. 12 at 8:12 AM
$ASRT Seems it is fixed now and I can post again wihout a warning
2 · Reply
Chuckuk
Chuckuk May. 12 at 8:11 AM
$ASRT check
0 · Reply
BigBadBeethoven
BigBadBeethoven May. 11 at 7:00 PM
$ASRT and oh yeah I forgot. Chainsaw Al was probably the most hated corporate Raider of all time. He didn't care. He would always say: "If you want to be loved... GET A DOG " GARDA is probably at the pound as we speak
1 · Reply
Polo2024
Polo2024 May. 11 at 6:02 PM
$ASRT Is people worried that the price will drop if the tender fails or is people recognizing this as a super low ball offer and will vote NO and wait for the market to give fairer value to Rolvedon? We bought Rolv close to $250M. Right now they are giving it away almost for free! We can stop wondering why they are doing this, it is clearly a plan from their greed and deception for personal gain. Talk high until is time to abandon ship with a big loot...
0 · Reply
Chuckuk
Chuckuk May. 11 at 12:15 PM
$ASRT ust seeing if this is a mistake I am restricted but not sure why I have not been as stroppy as some just sad about the current buyout proposal I dont think I have been rude or unresaonable?
2 · Reply
Chuckuk
Chuckuk May. 11 at 11:53 AM
$ASRT Looks like I have been banned
0 · Reply
BigBadBeethoven
BigBadBeethoven May. 11 at 8:29 AM
$ASRT DEAR GARDA: ATTN RAMBO IN PINSTRIPES: CHAINSAW AL DUNLAP RIDES AGAIN!!!!! This buyout brought to your attention by a SUNBEAM. Signed, ASRT Shareholders "If you wanna be liked... GET A DOG"
2 · Reply
Chuckuk
Chuckuk May. 11 at 12:54 AM
$ASRT Garda itself has no visible deal track record yet; Assertio/Rolvedon appears to be its first public transaction. The older examples back to 2010 or 2019/2020 are really Limber/Lund/Secura/Genoptix credentials, not Garda’s own corporate history.
0 · Reply